Tesla's Share Price Hits a New High This Year! Is It the Beginning or the End?

牛牛課堂

joined discussion · ·

Where is the next big opportunity in the U.S. stock market? ARKK has surged 50%, and during this rate-cutting cycle, closely follow Cathie Wood to seize investment opportunities!

Following the Federal Reserve's initiation of a rate-cutting cycle, the investment vehicle managed by 'Queen of Stocks' Cathy Wood $ARK Innovation ETF (ARKK.US)$ has demonstrated strong performance, with year-to-date gains nearing 50%, significantly outperforming the three major U.S. equity indices.

An analysis of the top ten holdings in Cathy Wood’s latest portfolio reveals that Tesla remains at the top, with primary bets placed on AI applications, AI healthcare, and cryptocurrency sectors.

In terms of year-to-date performance, $Tesla (TSLA.US)$ while the overall increase has been only 5%, recent momentum has been robust; in the area of AI applications $Roku Inc (ROKU.US)$ 、 $Roblox (RBLX.US)$ 、 $Shopify (SHOP.US)$ 、 $Palantir (PLTR.US)$ Increase by over 36%, 133%, 44%, and 140% respectively; cryptocurrency concept $Coinbase (COIN.US)$ 、 $Robinhood (HOOD.US)$ 、 $Bitmine Immersion Technologies (BMNR.US)$ Increase by over 37%, 230%, and 685% respectively; AI healthcare $Tempus AI (TEM.US)$ 、 $CRISPR Therapeutics (CRSP.US)$ Increase by over 160% and 58% respectively.

How to follow Cathie Wood’s investment strategy for profit?

Cathie Wood's investment career has been highly dramatic: In 2020, her flagship fund ARKK surged 152% during the pandemic by heavily investing in Tesla and other tech stocks, astonishing the market. However, during the growth stock downturn in 2022, ARKK suffered a significant drawdown of 67%, drawing widespread criticism. Yet, Wood remained steadfast, achieving a strong rebound of 67% in 2023, with gains of approximately 50% so far in 2025.

What is the secret to her success? It is not chasing short-term fluctuations,but firmly investing in those 'technologies that can reshape the future.'What is even more unique is her insistence on publicly disclosing all trading records daily. This unprecedented level of transparency allows ordinary investors to gain insight into the decision-making processes of top-tier funds.

Previously,Follow the 'Wooden Lady' Ark's Lead to Invest in the Future! A Deep Dive into ARKK’s Investment Portfolio: Who Has the Most Explosive Potential?An article noted that the 'Wooden Lady' made bold predictions about the landscape of technology investment for the next 5 to 10 years.

Cathie Wood proposed five major innovation platforms, including:Including artificial intelligence, robotics, energy storage, blockchain technology, and multi-omics sequencing,These are not isolated, but rather form a powerful synergistic network through technological integration, and their combined effect is reshaping the global industrial landscape.

In fact, the 'Wooden Lady' firmly believes that many of the large companies she holds will become major beneficiaries of the AI boom, including Tesla.A closer look at the 'Wooden Lady's' latest investment portfolio reveals significant bets on AI applications, AI healthcare, cryptocurrencies, and space defense.

Specifically:

The largest AI project on Earth—Tesla.

Based on Cathie Wood’s portfolio holdings, $Tesla (TSLA.US)$ Tesla is her top holding. Tesla’s recent stock price has been driven by multiple factors, including:Musk's increased stake, Tesla securing an autonomous vehicle testing permit in Nevada; Tesla unveiling revolutionary energy storage products Megapack 3 and Megablock systems; strong sales of Model Y L in China; and Musk's "trillion-dollar compensation package."

Cathie Wood has consistently been Tesla's strongest advocate on Wall Street. In March this year, she projected that Tesla’s stock price would reach $2,600 within five years. Wood predicts that by 2029, Tesla’s Robotaxi business will achieve scaled operations, with autonomous ride-hailing services potentially generating $951 billion in revenue opportunities for Tesla.

However, Tesla’s grand narrative extends far beyond Robotaxis. Its humanoid robot business, currently under development, is viewed as an engine of even greater growth potential. The key lies in the fact that humanoid robots share the same core technological platform as Robotaxis: robotics, energy storage (batteries), and artificial intelligence. Tesla has established a significant lead in these areas.

Cathie Wood stated that the current target price of $2,600 does not include the valuation of humanoid robots. However, she estimates that the global humanoid robot market could eventually reach an astonishing $26 trillion, with long-term potential that might even surpass the Robotaxi business.

馬斯克本人也曾直言，The humanoid robot business is expected to outpace autonomous driving, becoming Tesla’s largest growth driver in the future.

Notably, robotics and autonomous driving are also the two fields most favored by NVIDIA CEO Jensen Huang. Interested fellow investors can click to view more details.In the article 'Jensen Huang Defines the New Wave of AI! Physical AI May Usher in a New Era; Which Two Industries Are Likely to Take Off?', it was noted that:。

The cryptocurrency sector — Bitcoin is expected to reach $1.5 million.

Cathie Wood has consistently stated that Bitcoin remains in a bull market phase, with its price projected to reach $1.5 million by 2030. She believes Bitcoin will not only be an asset but also a rule-driven global currency.

Based on Cathie Wood’s portfolio, her holdings include $Coinbase (COIN.US)$ 、 $Robinhood (HOOD.US)$ 、 $Bitmine Immersion Technologies (BMNR.US)$ 、 $Circle (CRCL.US)$ 、 $Bullish (BLSH.US)$ 。Notably, Bitmine has become one of its top ten holdings.

The market widely regards this as "Cathie Wood's" positive affirmation of Bitmine’s long-term growth potential. She even posted on the X platform stating: "Such companies could emerge as the next generation of asset management firms in the era of on-chain capital markets."

Notably, in addition to "Cathie Wood," tech magnate Peter Thiel also recently revealed that his venture capital fund holds a 9.1% stake in Bitmine.

Moreover, after Bullish went public, although Cathie Wood temporarily exited at a high point for profit-taking, ARKK re-entered the position once the company’s price retreated, currently holding 1.66 million shares.

Meanwhile, Bullish’s latest earnings results did not disappoint Ms. Wood. For the second quarter ended June 30, the company reported a net profit of $108.3 million, a striking contrast to a net loss of $116.4 million in the same period last year. This marks a significant turning point for the company post-IPO, with its stock surging over 20% following the earnings announcement.

The Most Profound Application of AI — The Healthcare Sector

AI is curing diseases that were previously incurable.

Ms. Wood stated in an interview earlier this year,The most profound application of AI will emerge in the healthcare sector.

Because of AI, we are now able to diagnose cancer at stage one with a single blood test. Think about what this means.It means that AI can save the lives of many people.」

Specifically, in the medical field, AI can rewrite the underlying logic of disease treatment, improve the efficiency of drug development, and promote the commercial application of multi-omics sequencing, among others.

Looking at the AI healthcare stocks held by Cathie Wood, they cover subfields such as gene editing, precision medicine, drug development, and diagnostic testing:

1. Gene Editing and Gene Therapy

$CRISPR Therapeutics (CRSP.US)$：Gene-editing treatments for hereditary diseases (e.g., thalassemia, sickle cell anemia).This company has developed a therapy that can cure sickle cell disease and β-thalassemia with a one-time treatment. Patients with these conditions used to require 10 to 20 emergency room visits per year for blood transfusions to sustain their lives. Now, they have the opportunity to live a normal life.

$Beam Therapeutics (BEAM.US)$：Base editing technology (single-base modification) for treating genetic diseases (such as hereditary liver disease and blood disorders).Unlike traditional CRISPR cutting, Beam's base editing technology only replaces a single base on the DNA, avoiding double-strand breaks and resulting in fewer side effects,making it suitable for the gene repair of chronic diseases caused by single-point mutations.

$Intellia Therapeutics (NTLA.US)$ In vivo gene editing (delivery of CRISPR components via lipid nanoparticles (LNP) to directly repair defective genes in the patient's body).

2. Synthetic biology and DNA design (AI-driven biomanufacturing)

$Twist Bioscience (TWST.US)$Synthetic biology core tools platform, Twist provides high-throughput DNA synthesis services, offering standardized and scalable 'molecular building blocks' to pharmaceutical companies, research institutions, diagnostic firms, and others. It does not directly engage in drug development but focuses on the rapid manufacturing of 'designed molecules,' serving as a supplier of foundational components for biological experiments.

3. Precision medicine

$Tempus AI (TEM.US)$ : A precision medicine platform.Its core mission is to leverage AI and one of the largest clinical and molecular databases globally to accelerate the development of precision medicine.The company assists doctors and researchers in providing more accurate diagnoses and personalized treatment plans for patients with cancer and other complex diseases through genomic sequencing, medical data analysis, and an AI platform. It also accelerates the process of new drug development and clinical trials, aiming to improve patient outcomes.

$10x Genomics (TXG.US)$ is a leading life sciences technology company dedicated to developing innovative tools for single-cell and spatial multi-omics analysis.

$GeneDx Holdings (WGS.US)$ ：The company's mission is to end the 'newborn guessing game' through genomics.Traditional newborn screening relies on diagnosis after symptoms appear or on limited testing methods, often missing the critical treatment window. For instance, some rare diseases are only detected when infants exhibit seizures or abnormal breathing, leading to delayed treatment.

GeneDx, however, uses whole-genome sequencing to analyze infant blood samples and quickly identify genetic defects that may cause epilepsy or heart disease. Thanks to the powerful data processing capabilities of AI, its testing cycle has been reduced from a week to 2-3 days. In neonatal ICUs, this 'speed' can be life-saving—doctors can directly prescribe precise treatments based on the results.

4. Drug Development

$Recursion Pharmaceuticals (RXRX.US)$ is a biotechnology company committed to accelerating drug discovery and development through large-scale automated experiments and AI. Its core approach involves generating and analyzing vast biological and chemical datasets to uncover new disease mechanisms and potential therapeutic molecules.

5. Gene Sequencing and Data Analysis

$Illumina (ILMN.US)$ : Focused on the research, development, and supply of gene sequencing equipment. Recently launched PromoterAI, a new tool that assists in identifying gene regulatory variations in non-coding regions, which can help improve the efficiency of rare disease diagnosis.

6. Liquid Biopsy for Cancer (AI-based analysis of circulating tumor DNA/biomarkers)

$Exact Sciences (EXAS.US)$：The company focuses primarily on early cancer screening and precision treatment; its product Cologuard is a market leader in colorectal cancer screening, while Oncotype DX provides gene testing for precision breast cancer treatment, acquired through acquisition.

$Natera (NTRA.US)$ : Non-invasive prenatal testing (NIPT) and post-surgical cancer recurrence monitoring (MRD). This diagnostics company specializes in cell-free DNA (cfDNA) testing, with operations spanning oncology, women's health, and organ transplantation. In women’s health, Panorama™ offers non-invasive prenatal testing, and Horizon™ conducts carrier screening.

In the field of oncology, Signatera™ is a personalized, tumor-informed minimal residual disease (MRD) testing product used to monitor cancer recurrence and treatment response. Additionally, Prospera™ is used to assess the risk of organ transplant rejection.

$Veracyte (VCYT.US)$ This company's products are designed to enhance the diagnostic accuracy of various diseases, including thyroid cancer, prostate cancer, and breast cancer, among other clinical scenarios. A common feature of these products is that they do not rely on histological assessment but instead analyze RNA expression patterns to determine whether cells exhibit abnormal activity.

Additionally, Cathie Wood has also invested in gene sequencing companies $Pacific Biosciences of California (PACB.US)$ , medical equipment $Cerus (CERS.US)$ 。

To learn more about AI healthcare companies, click to view“'AI + Healthcare' Gains Support from Pelosi and Cathie Wood! In addition to Tempus AI, what other investment opportunities are there in this field?”。

Comprehensive AI industry chain layout

Cathie Wood has also invested heavily in AI application stocks such as $Roku Inc (ROKU.US)$ 、 $Roblox (RBLX.US)$ 、 $Shopify (SHOP.US)$ 、 $Palantir (PLTR.US)$ 、 $Amazon (AMZN.US)$ 、 $Meta Platforms (META.US)$ 、 $PagerDuty (PD.US)$ 、 $Gitlab (GTLB.US)$ 、 $Pinterest (PINS.US)$ 、 $DraftKings (DKNG.US)$ 、 $Airbnb (ABNB.US)$ 、 $The Trade Desk (TTD.US)$ ；

as well as semiconductor stocks $Advanced Micro Devices (AMD.US)$ 、 $Teradyne (TER.US)$ 、 $NVIDIA (NVDA.US)$ 、 $Taiwan Semiconductor (TSM.US)$ 。

Space & Defense & Drones

Artificial intelligence will also deeply penetrate the defense and space sectors, for example, by using autonomous drones to protect soldiers' safety.

Cathie Wood has placed a bet on , a U.S. defense technology company providing mobile communication services via low Earth orbit satellites, $Iridium Communications (IRDM.US)$ and $Kratos Defense & Security Solutions (KTOS.US)$ and a leader in the EVTOL (flying car) sector $Archer Aviation (ACHR.US)$ . Archer Aviation not only has strong prospects in the electric vertical takeoff and landing vehicle (eVTOL) field but is also gradually entering the AI domain within the US military.

In addition to the aforementioned industries, 'Wood姐' also holds stakes in agriculture + robotics $Deere (DE.US)$ , nuclear power companies $BWX Technologies (BWXT.US)$ , and fintech $Block (XYZ.US)$ 、 $SoFi Technologies (SOFI.US)$ and so on.

Despite the controversies surrounding 'Wood姐', her investment philosophy—marked by a bold divergence from market consensus—remains worthy of study by investors. She avoids the crowded AI chip sector, opting instead to focus on AI healthcare; when defense stocks were overlooked, she steadfastly recognized the transformative potential of AI. This unique perspective reminds us: the ultimate goal of investing is to grow alongside technologies that change the world, rather than being swept away by fleeting trends.

194

1.6M Views